Keybanc Maintains Overweight on ResMed, Lowers Price Target to $266

Benzinga Newsdesk www.benzinga.com Negative 92.2%

Neg 92.2% Neu 0% Pos 0%

Keybanc analyst Justin Patterson maintains ResMed (NYSE:RMD) with a Overweight and lowers the price target from $290 to $266.